Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis

1999 ◽  
Vol 29 (4) ◽  
pp. 529-536 ◽  
Author(s):  
VERIN ◽  
DICKER ◽  
MORTEMOUSQUE
2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Hiroyuki Yazu ◽  
Kazumi Fukagawa ◽  
Eisuke Shimizu ◽  
Yasunori Sato ◽  
Hiroshi Fujishima

Abstract Background Because atopic dermatitis does not heal completely, associated severe atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) often require long-term treatment. This study aims to evaluate the long-term outcomes of using 0.1% tacrolimus eye drops to treat these severe allergic conjunctival diseases. Methods Two-hundred-and-seventy eyes of 135 patients diagnosed with AKC or VKC from April 2004 to April 2014 were screened retrospectively. Patient demographics and objective signs were extracted from the electronic medical records. The severity of 10 objective signs, related to the palpebral and bulbar conjunctiva, limbus, and cornea, and intraocular pressure (IOP) were observed at baseline, at 2 weeks, 1, 2, 3, 6, and 12 months after starting treatment, and every 1 year thereafter (average use period: 8.4 ± 2.9 years). Safety was evaluated based on the incidence and severity of adverse events. Results 12 patients (AKC; 7 cases, VKC; 5 cases) who were treated with 0.1% tacrolimus eye drops were enrolled in this study. The total score of clinical signs significantly decreased after 2 weeks and remained effective thereafter. Tacrolimus eye drops elicited a statistically significant difference in the mean total clinical scores and IOP over the course of treatment (P < 0.001). Elevated IOP was observed in 2 cases and corneal infection in 1 case; these effects were completely controlled with medication. Conclusions Topical tacrolimus may provide effective and long-term improvement in clinical signs of severe AKC and VKC cases that refractory to standard conventional treatment. Trial registration: University Hospital Medical Information Network (UMIN) 000034460.


2018 ◽  
Vol 02 (01) ◽  
Author(s):  
Katrin Lorenz ◽  
Gerhard Garhofer ◽  
Sonja Hoeller ◽  
Ward Peterson ◽  
Raimund M Vielnascher ◽  
...  
Keyword(s):  
Dry Eye ◽  

2020 ◽  
Vol 10 (1) ◽  
pp. 47-52
Author(s):  
Lylys Surjani ◽  

Vernal keratoconjunctivitis (VKC) is an allergic eye disease with a chronic inflammatory condition, mostly bilateral, and affects upper tarsal conjunctiva. VKC is characterized by conjunctival infiltration by various types of inflammatory cells, especially eosinophils, although VKC was previously considered an IgE-mediated disease, but several other immunological pathways such as an increase of activated CD4 + T-lymphocytes, especially Th2, which indicates that hypersensitivity reactions are found against unknown pathogens. The rate of eye infection with shield ulcers ranges from about 9-10% which Staphylococcus epidermidis and Streptococcus pneumonia are the most common bacteria founded. Patients with VKC often present with symptoms which are intense itching, hyperemia conjunctiva, and watery eyes, photophobia, and a sensation like a foreign object. Clinical signs of VKC include papillary reactions of the upper tarsal conjunctiva and throughout the limbus. When eyelid eversion, bulbar and tarsal conjunctival hyperemia can be observed in the presence of papillae of varying size and occasionally a gelatinous infiltrate in the limbus area (Trantas Horner's nodule) which is necessary for the diagnosis of VKC. Avoiding specific/nonspecific triggers can prevent severe manifestations of VKC. Topical lubrication with artificial tears is used for long-term management of VKC patients, both during the active and passive phases. The main focus of VKC medical management is to relieve symptoms and prevent complications, the types of medications used include antihistamines, mast cell stabilizers, steroids, and immunosuppressive eye drops (Cyclosporin A (CsA) & Tacrolimus). Supratarsal injection of either short or medium acting corticosteroids is recommended as a therapeutic approach in patients with VKC. Excision of the giant papilla of tarsal conjunctiva with 0.02% intraoperative mitomycin-C was recommended in cases resulting in ptosis.


2007 ◽  
Vol 221 (3) ◽  
pp. 153-158 ◽  
Author(s):  
Eiichi Uchio ◽  
Yuki Itoh ◽  
Kazuaki Kadonosono

Sign in / Sign up

Export Citation Format

Share Document